Search PubMed⌕ Search

Biomedical subjects

C Manegold

Publications and source records attributed to C Manegold.

At least 109 records · Page 6Linked to original sources
PubMed1990

Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

The object of the study was to evaluate the effectiveness of ifosfamide/etoposide and mesna therapy in advanced breast cancer. A total of 44 patients with breast cancer were included in the trial. Eligibility criteria included measurable, refractory disease; prior anthracycline therapy (or its contraindication); a life expectancy of at least 3 months; and adequate hepatic, renal, CNS and bone marrow function. All patients were less than or equal to 70 years of age and had a Karnofsky performance status of greater than or equal to 50%. There were 36 evaluable cases. Sites of metastatic disease included bone (19), skin (18), liver (9), lung (14), lymph node (19), and miscellaneous (7). Treatment consisted of 1,500 mg/m2 ifosfamide given i.v. on days 1-5, 120 mg/m2 etoposide given i.v. on days 1-3, and 400 mg i.v. mesna given with and at 4 and 8 h after ifosfamide. Cycles were repeated every 28 days. Initial doses were reduced by 25% or 50% in patients who had previously undergone both chemotherapy and radiotherapy. A median of 4 cycles (range, 2-8) were given. The myelotoxicity was marked: WHO grades 3/4 leukopenia (n = 37), grades 3/4 thrombocytopenia (n = 12), and grades 2/3 anemia (n = 13). Due to myelotoxicity, dose reduction or prolongation of treatment-free intervals was necessary in 28 cases. Alopecia was seen in 35 patients and CNS toxicity, in 8. Partial remission (PR) was obtained in five cases and complete remission (CR), in three. Sites of response included the lung (5), skin (4), lymph node (5), and peritoneum (1). The duration of response was 4 (n = 2) and 8 (n = 1) months for CR and 2 (n = 2), 6 (n = 2), and 10 (n = 1) months for PR. We conclude that the ifosfamide/etoposide and mesna regimen is effective, but its myelotoxicity is treatment-limiting.

Adult↗
PubMed1990

Etoposide, adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer. A phase II trial by the "Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)".

In a multicenter trial, 49 patients with histologically proven advanced gastric cancer were treated with a combination chemotherapy consisting of etoposide 120 mg/m2 d 4, 5, 6 adriamycin 20 mg/m2 d 1, 7 and cisplatinum 40 mg/m2 d 2, 8. Therapy was repeated every 4 weeks, 45 patients were evaluable for response after 8 weeks of treatment. Eight patients achieved a partial remission (PR: 18%), 17 patients had no change (NC: 38%), and 20 patients showed tumor progression (P: 44%). Four patients with primarily inoperable tumor and without distant metastases who achieved a partial remission, underwent second look operation with curative intention. All 4 patients died within 12 months after second look operation due to tumor recurrence. Median survival time of all patients was 9 months. Toxicity was considerable. WHO grade 3/4 toxicity appeared in 20-30% of patients (nausea, vomiting, loss of appetite, leucopenia). After 3 cycles complete alopecia was present in 70% of patients. Severe infection, requiring treatment, occurred in 10 patients. Five patients discontinued therapy because of intolerable subjective toxicity. The observed response rate of 18% objective partial remissions is disappointing and does not give support to the communications reporting response rates over 50% with EAP and other regimens including cisplatinum. In conclusion, and considering the high subjective and objective toxicity of this regimen, it can not be recommended for standard use in patients with advanced gastric cancer.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

[Prognostic factors in small cell bronchial cancer].

199 cases with small cell lung cancer, which appeared in our hospital records between 1980 and 1981, and which could be followed up to the end of 1987, were retrospectively analyzed. For our analysis of the evaluation of prognostic factors we utilized the Kaplan-Meier system as well as the Log-Rank test. Factors of prognostic significance were: sex, stage of disease, the N-status as well as the M-status.

Carcinoma, Small Cell↗
PubMed1989

Iliac crest needle biopsy as a method for determining estrogen receptors in bone metastases from breast cancer.

The purpose of our study was to clarify whether the amount of tissue extracted by means of iliac crest needle biopsy (ICNB) would suffice for a quantitative determination of estrogen receptors (ER) in bone metastases, and to see if the method currently used for determining ER in primary tumors could also be successfully utilized in ICNB. 22 of 31 breast cancer patients examined could be evaluated. ER was positive in 7 (31.8%). Reasonable data are to be expected when the biopsy weight exceeds 0.1 g. Our study confirms that the necessary amount of tissue for ER analysis can indeed be extracted by ICNB. Our results justify further studies on a larger group of patients, since we cannot make conclusive statements concerning the value of this method for predicting the ultimate success of an endocrine treatment.

Adult↗
PubMed1989

Value of bilateral iliac crest needle biopsy for pretherapeutic tumor staging of bronchogenic carcinomas.

Two hundred and forty-three patients with lung cancer were biopsied pretherapeutically and bilaterally on the anterior iliac crest. Tumor infiltration into the bone marrow could be demonstrated in 7 patients. No tumor-positive biopsies were found in the 163 patients with non-small cell lung cancer (NSCLC). In small cell lung cancer (SCLC), however, the infiltration rate was 9% (7/80). In 3 of the 7 patients (43%) only 1 of the 2 sides biopsied had been infiltrated. All 7 patients with tumor-positive bone marrow samples were found to have additional metastases elsewhere (stage IV, 7/26; 27%). Therefore, according to our results, we cannot recommend iliac crest biopsy as a routine pretherapeutic procedure to aid in the staging of SCLC and NSCLC.

Adult↗
PubMed1988

The value of bone marrow examination for tumor staging in breast cancer.

The purpose of our study was to investigate the value of cytokeratin antibodies for identifying bone marrow involvement in breast cancer patients who showed no evidence of distant metastases using noninvasive tumor staging procedures. Bone marrow for histological (biopsy) and immunocytochemical (aspiration) evaluation was obtained from the anterior iliac crest from 50 unselected consecutive women during surgical treatment of the primary tumor. The histological examination was done on nondecalcified bone sections. The immunocytochemical studies were carried out on interface smears of the bone marrow aspirates. For staining, cytokeratin antibodies (PKK 1) and the immune alkaline phosphatase method was used. Cytokeratin-positive cells were found in 4 of the 50 cases (8%). Of those 4 patients, however, 2 also showed evidence of neoplastic bone marrow infiltration histologically. We thus were able to prove that immunocytochemistry on aspirates is superior to conventional histology in identifying tumor in bone marrow. Nonetheless, our results clearly fell below the rate found in previous studies where epithelial membrane antigen antibodies were used.

Bone Marrow↗
PubMed1986

Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.

This report is concerned with therapeutic studies utilizing new bisphosphonic acids on tumor-induced osteolytic metastases. The bone metastases on SD rats were induced by intraarterial and intraosseous transplantation of Walker carcinosarcoma 256 B ascites cells. The treatment was carried out using disodium-3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP), diglycidyl-[3-(3, 3-bisphosphono-3-hydroxy-propylamino)-2-hydroxypropyl-]urazol++ +-Na2 (DDU) and 1,2,4-triglycidylurazol (TGU). The extent of bone metastases was determined by X-ray on the 5th and 10th days following tumor inoculation, as well as both microradiographically and histologically upon termination of the experiment. High dose DDU produced a clear reduction of the tumor osteolysis, but these positive results were surpassed using APD. The best results were achieved by pretreatment with APD 24 h prior to tumor inoculation.

Animals↗
PubMed1985

Vascularization of malignant testicular tumors.

Recent studies of malignant testicular tumors report a correlation between vascularization, biologic behavior, radiosensitivity, and chemotherapeutic response of the tumor. Postoperative angiographies of malignant testicular tumor specimens (seminoma n = 4, nonseminoma n = 12) showed the following results: Contrary to the symmetric vascularity pattern of normal testes, seminomas were hypovascular, well-defined from normal testicular tissue and not neovascular. Nonseminomas showed isovascularity (n = 5) or hypovascularity (n = 7) but with focal hypervascular areas in the tumor (n = 10), and pathologic neovascularization. Present angiographic studies reveal marked differences in the vasculature pattern of malignant testicular tumors. In nonseminomas, focal hypervascular or neovascular areas as centers of a high-growth rate correlate well with comparable cell kinetic studies. Assuming a similar growth behavior in metastases, the vascularization type of these growth centers theoretically favors the efficient use of chemotherapeutic agents.

Arteries↗
PubMed1982

[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)].

A sequential combination of methotrexate and 5-fluorouracil was used for treatment of 20 patients with metastasizing colorectal carcinomas. Pretreatment with 5-fluorouracil had been given to five patients. While the chemotherapeutically pretreated patients showed two partial remissions, two minimal remissions and one progression, the remaining patients showed one full remission, six partial remissions, five minimal remissions and three progressions. The average partial remission time of these patients was 7,9 months. The average survival time will probably be more than one year. The toxicity of treatment was slight.

Adult↗
PubMed1980

[Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)].

Growth arrest and renal osteodystrophy are major problems in renal insufficiency of children. The present report describes our experiences in managing renal osteodystrophy in 14 dialyzed children using 1,25-DHCC for 12 months. Values in plasma of Ca, P, Mg, alkaline phosphatase, iPTH, 25-OH-D, and 1,25-DHCC were determined regulary. Skeletal X-rays and analysis of iliac crest biopsies were obtained in each child. In treatment with 1,25-DHCC episodes of severe but reversible hypercalcemia occurred. Alkaline phosphatase and iPTH normalized completely. Radiographic examinations revealed marked improvement. Histological signs of fibro-osteoclasia and resorptive defects disappeared but there was no recovery of osteomalacia. A reduction of osteoblast population and of bone transformation was obvious. 1,25-DHCC failed to normalize growth in uremic children. In short, neither vitamin D nor 1,25-DHCC can guarantee complete recovery of renal osteodystrophy and growth arrest in uremic children.

Adolescent↗
PubMed1980

[Left axis deviation and left anterior hemiblock in patients with essential hypertension during antihypertensive treatment (author's transl)].

The ECG's of 127 patients (81 men and 46 women) with uncomplicated essential hypertension were evaluated over a 4-year period of antihypertensive treatment. At the beginning of the study in 1973, 39 men (48%) showed ECG changes of left axis derivation (LAD) and 8 men (10%) a left anterior hemiblock (LAH), while 19 women (41) showed a LAD and 4 (9%) a LAH. During the course of the study no changes were noted in the 12 cases of LAH. However, two additional men developed signs of LAD in 1975/76 and one more in 1977/78. Men with LAH were somewhat older and women with LAH heavier in comparison to the total group. The combination of LAD and left ventricular hypertrophy (LVH) was evident in 9 men (11%) and 4 women (9%) at the beginning of the study, while 6 men (7%) and 1 woman showed a combination of LAH and LVH. Reversibility of LVH by ECG was observed in 10 patients (50%), but no concomitant changes in axis deviation were seen.

Antihypertensive Agents↗